AGIO (Agios Pharmaceuticals) Future Price to Earnings

The change in the forward P/E ratio of Agios Pharmaceuticals (AGIO) confirms the status of Agios Pharmaceuticals (AGIO) as a cellular metabolism innovator trusted by patients with rare pathologies. The 0.00 level serves as a critical analytical benchmark. Royalties from legacy patents provide the financial foundation, guaranteeing a stable cash flow. A massive liquidity reserve protects the business from market pressure during the development of new drugs.

AGIO - Agios Projected Price to Earnings Ratio over the range 07/04/2022 - 11/15/2026

Analytical breakdowns for Agios Pharmaceuticals

- current price and projected stock value:

Stock Quotes Agios Pharmaceuticals Inc|AGIO - Fair Value Consensus

- business market valuation indicators:

Market Value Agios Pharmaceuticals|AGIO - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Value per Share Agios Pharmaceuticals|AGIO - Total Stockholders' Equity|Market Cap to Net Assets Ratio agios.com|AGIO - Aggregate Business Assets

- issuer credit burden and liquidity indicators:

- earnings and market ratios statistics:

AGIO - Net Financial Result|Expected Profit Agios Pharmaceuticals|AGIO - Business Payback Period|Future Price to Earnings agios.com|AGIO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Agios Pharmaceuticals Inc|AGIO - Operating profit EBITDA|Net earnings per share (EPS TTM) Agios Pharmaceuticals|AGIO - Net earnings per share for the trailing year|Quarterly EPS earnings growth agios.com|AGIO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Agios Pharmaceuticals

- sales and revenue data:

AGIO - Company Total Revenue|Company Projected Revenue Agios Corp|AGIO - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Agios Pharmaceuticals|AGIO - Revenue Dynamics YoY (Last Twelve Months)

General company analysis:AGIO agios.com

Forward P/E is calculated as the ratio of current market capitalization to expected net income, measuring the market's willingness to pay a premium for future earnings. For Agios Pharmaceuticals (AGIO), where robotic synthesis accelerates development, the company's forward P/E metric reflects the balance between technological optimism and clinical trial risks, making it possible to distinguish fundamental growth from a temporary speculative rally.

Competitors of Agios Pharmaceuticals (AGIO)